MDWD
MediWound
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
MDWD Profile
Mediwound Ltd.
A fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration
42 Hayarkon Street, Yavne , 8122745 Israel
--
MediWound Ltd., was legally incorporated in Israel on January 27, 2000. It is a fully vertically integrated biopharmaceutical company focused on developing, producing and commercializing new products to meet the therapeutic needs in the areas of severe burns, chronic and other difficult-to-heal wounds and connective tissue diseases. Its innovative biomedical product NexoBrid was approved for marketing by the European Medicines Agency (EMA) in December 2012 to remove dead or damaged tissue (i.e. eschar) and treat local and systemic thermal burns (i.e. severe burns). NexoBrid, based on its patented proteolytic enzyme technology, represents a new model in burn care, and the company's clinical trials have shown statistically significant that patients can achieve rapid early eschar removal without hospitalization, non-surgical, and no additional tissue damage. Through its wholly-owned subsidiary in Germany, the company launched NexoBrid in the EU in December 2013, targeting burn patients in burn centers and hospital burn units. The company also plans to initiate a Phase 3 pivotal study in the United States in the first half of 2014 to file a biological product license application (or BLA) with the U.S. Food and Drug Administration (FDA). The company's headquarters in Yavne, Israel has a state-of-the-art, EMA-certified, CGMP-compliant, sterile pharmaceutical manufacturer. And NexoBrid is produced here.